Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
46 Results for "
EPHA2
" in MedChemExpress (MCE) Product Catalog:
Products (46)
46 Results for "EPHA2" in MCE Product Catalog:
9
9 Publications Verification
Synonyms: BHG712
Target:
Research Areas:
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively [2].
2
2 Cited Publications
Target:
Research Areas:
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 .
1
1 Cited Publications
Cat. No.: HY-P10579
CAS No.: 2225868-19-7
Target:
Research Areas:
1
Cat. No.: HY-P990627
Synonyms: MEDI-547 antibody
Target:
Research Areas:
Cat. No.: HY-P991577
Synonyms: DS-8895A
Target:
Research Areas:
Cat. No.: HY-P10412
CAS No.: 2412926-30-6
Synonyms: ANXA1-derived 11 amino acid-long peptide
Target:
Research Areas:
Target:
Research Areas:
EphA2 agonist 1 (Compound 7bg) is a potent EphA2 receptor agonist. EphA2 agonist 1 shows great potency and selectivity toward EphA2 overexpressed glioblastoma cells and stimulates EphA2 phosphorylation .
Target:
Research Areas:
UniPR129 is a potent and orally active Eph/ephrin antagonist. UniPR129 can inhibit EphA2-ephrin-A1 interaction with an IC50 of 945 nM and a Ki of 370 nM. UniPR129 can inhibit angiogenesis and show antitumor and neuroprotective effect. UniPR129 can be used for the researches of cancer and neurological disease, such as colorectal cancer and optic neuropathy [2] .
Cat. No.: HY-P3717
CAS No.: 3031514-44-7
Target:
Research Areas:
Cat. No.: HY-169849
CAS No.: 1428095-28-6
Target:
Research Areas:
EphA2 antagonist 1 (4b) is a bile acid conjugate and an ephrin type-A receptor 2 (EPHA2) inhibitor .
Synonyms: 3,4,8,9-Tetrahydroxy urolithin
Target:
Synonyms: 113B7
PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer [2] .
Cat. No.: HY-170517
CAS No.: 3065631-84-4
Target:
Research Areas:
PKMYT1-IN-8 (Compound 137) is the inhibitor for PKMYT1 with an IC50 of 9 nM. PKMYT1-IN-8 inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2with IC50s of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. PKMYT1-IN-8 inhibits the proliferation of cancer cell OVCAR3 with GI50 of 2.02 μM .
Cat. No.: HY-146141
CAS No.: 2169273-66-7
Target:
Research Areas:
EphA2 agonist 2 (Lead compound) is a selective EphA2 agonist with antitumor activities. EphA2 agonist 2 can cross the BBB .
Cat. No.: HY-146375
CAS No.: 2938227-14-4
Target:
Research Areas:
UniPR505 (Compound 14) is an EphA2 antagonist with an IC50 of 0.95 µM. UniPR505 displays anti-angiogenic properties .
Cat. No.: HY-W078239
CAS No.: 313701-92-7
Target:
Research Areas:
EPHA4 antagonist-1 (Compound 2) is an EphA4 receptor antagonist. EPHA4 antagonist-1 is also an EphA2 receptor antagonist. EPHA4 antagonist-1 inhibits ephrin-A5 AP binding to EphA4 Fc receptor, with an IC50 of 10 μM .
Cat. No.: HY-159174
Research Areas:
EPHA2/A4/GAK-IN-1 (compound 55) is a potent inhibitor of EPHA2/EPHA4 and GAK with KD values of 180.5 nM for EPHA2 and 19.2 nM for GAK, respectively. EPHA2/GAK-IN-1 shows an extrapolated half-life time of 4.6 h in a microsomal stability assay. EPHA2/GAK-IN-1 shows antiviral activity and prevents dengue virus infection of Huh7 liver cells .
Cat. No.: HY-P10412A
Synonyms: ANXA1-derived 11 amino acid-long peptide acetate
Target:
Research Areas:
A11 (ANXA1-derived 11 amino acid-long peptide) acetate is a ANXA1-EphA2 interaction-blocking peptide. A11 acetate reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 acetate inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 acetate inhibits angiogenesis. A11 acetate can be used in studies related to nasopharyngeal carcinoma .
Cat. No.: HY-RS04426
Target:
Research Areas:
EPHA2 Human Pre-designed siRNA Set A contains three designed siRNAs for EPHA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
